A Johnson & Johnson subsidiary could face penalties for not reporting incidents where insulin pumps failed to operate, according to a recent letter from the Food and Drug Administration. The correspondence also alleged that Animas Corp. failed to establish an adequate system for reporting medical device mishaps.
